Aerie boosted as Valeant's troubled Tampa facility looks like it's coming out of rehab
Just days after Valeant $VRX and its late-stage eye drug latanoprostene bunod were turned away by the FDA for the second time after its Bausch + Lomb manufacturing facility in Tampa failed to measure up to federal standards, the troubled biotech says it’s clearly on track to now snag a clean bill of health from inspectors.
And while Valeant still has to refile, once again, the news buoyed shares of Aerie, which relies on the facility for its supplies of Rhopressa, a glaucoma drug now under review at the FDA.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
